Marksans Pharma Limited
MARKSANS · NSE · ₹326 a share (close of 01 Oct 2026)
Available company data, source links and archived checks for Marksans Pharma Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Revenue rose 35.6%; Net profit was ₹159.41 crore.
Quarter ended 2026-06-30 · consolidated · Company filing
Recorded quarterly figures
| Quarter | Revenue / income | YoY |
Profit | YoY | Net margin | Source |
|---|
| Jun 2026 | Revenue: ₹841 cr | +35.6% | Net profit: ₹159 cr | +173.9% | 19.0% | Company filing source |
| Mar 2026 | Revenue: ₹856 cr | +1108.4% | Net profit: ₹149 cr | +1542.7% | 17.4% | Company filing source |
| Dec 2025 | Revenue: ₹754 cr | — | Net profit: ₹114 cr | — | 15.1% | Company filing source |
| Sep 2025 | Revenue: ₹720 cr | — | Net profit: ₹99 cr | — | 13.8% | Company filing source |
| Jun 2025 | Revenue: ₹620 cr | +5.0% | Net profit: ₹58 cr | -34.7% | 9.4% | Company filing source |
| Mar 2025 | Revenue: ₹71 cr | — | Net profit: ₹9 cr | — | 12.8% | Company filing source |
YoY means change from the same quarter a year earlier.
— means no comparable figure is available. Older entries with incomplete source
details have not been revalidated under the current checks.
Who holds it — from the filings
MARK SALDANHA 43.8%ORBIMED ASIA IV MAURITIUS FVCI LIMITED 8.6%UTI-HEALTHCARE FUND 2.1%KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK SPECIAL OPPORTUNITIES FUND 1.1%SANDRA SALDANHA 0.1%register as filed
2026-06-30
Filing timeline — what the company told the exchange
- Marksans Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015…
25 Sep 2026 · document
- General Updates. Marksans Pharma Limited has informed the Exchange regarding opening of Special Window for Re-lodgment of Transfer Requests of Physical Shares…
17 Sep 2026 · document
- Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company …
07 Sep 2026 · document
- Analysts/Institutional Investor Meet/Con. Call Updates. Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet…
01 Sep 2026 · document
- Shareholders meeting. Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on Au…
27 Aug 2026 · document
- Shareholders meeting. Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026…
27 Aug 2026 · document
- General Updates. Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & A…
26 Aug 2026 · document
- Analysts/Institutional Investor Meet/Con. Call Updates. Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet Q1 FY 27 Fi…
20 Aug 2026 · document
Follow this company without reading every document yourself.
Keep its available filings, dated fact checks and disclosure alerts together.
Your saved country sets your market and its research schedule.
Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment
advice · cancel any time